Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).
BMO says Eylea court decision ‘modest negative’ for Regeneron
BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...
Jim Cramer On Regeneron Pharmaceuticals Inc. (REGN) – “I Want You to Own It”
We recently published a list of What Did Jim Cramer Say About These 19 Stocks Recently? In this article, we are going to take ...
Appeals court upholds denial of Regeneron motion for injunction against Amgen
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
news.bloomberglaw1d
Amgen Keeps Win Over Regeneron Bid to Block Eylea Biosimilar
Regeneron Pharmaceuticals Inc. failed to convince the Federal ... the Federal Circuit said in a precedential opinion issued Friday. “Amgen had discovered a way to prepare and formulate the active ...
Court asked to intervene after email tells USAID workers to destroy classified documents
A union for U.S. Agency for International Development contractors is asking a federal judge to intervene in any destruction ...